Technical Analysis for SAGE - Sage Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 76.4 3.12% 2.31
SAGE closed up 3.12 percent on Friday, January 17, 2020, on approximately normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical SAGE trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Fell Below 20 DMA Bearish 3.12%
NR7 Range Contraction 3.12%
180 Bearish Setup Bearish Swing Setup 1.99%
Pocket Pivot Bullish Swing Setup -0.37%
Bearish Engulfing Bearish 2.18%
Stochastic Sell Signal Bearish 2.18%
Upper Bollinger Band Touch Strength 2.18%
Pocket Pivot Bullish Swing Setup -1.09%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
Chemistry Biopharmaceutical Physical Sciences Drugs Antidepressants Gabaa Receptor Positive Allosteric Modulators Adjunctive Therapy Anticonvulsants Neurosteroids

Is SAGE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 193.56
52 Week Low 56.5
Average Volume 1,273,155
200-Day Moving Average 148.76
50-Day Moving Average 102.34
20-Day Moving Average 74.68
10-Day Moving Average 75.60
Average True Range 3.99
ADX 33.18
+DI 19.16
-DI 28.97
Chandelier Exit (Long, 3 ATRs ) 67.04
Chandelier Exit (Short, 3 ATRs ) 79.86
Upper Bollinger Band 77.73
Lower Bollinger Band 71.62
Percent B (%b) 0.78
BandWidth 8.17
MACD Line -5.87
MACD Signal Line -8.26
MACD Histogram 2.3875
Fundamentals Value
Market Cap 2.86 Billion
Num Shares 37.4 Million
EPS -6.09
Price-to-Earnings (P/E) Ratio -12.55
Price-to-Sales 0.00
Price-to-Book 8.73
PEG Ratio 0.72
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 80.45
Resistance 3 (R3) 80.13 78.47 79.78
Resistance 2 (R2) 78.47 77.44 78.63 79.55
Resistance 1 (R1) 77.43 76.80 77.95 77.75 79.32
Pivot Point 75.77 75.77 76.03 75.93 75.77
Support 1 (S1) 74.73 74.74 75.25 75.05 73.48
Support 2 (S2) 73.07 74.10 73.23 73.25
Support 3 (S3) 72.03 73.07 73.03
Support 4 (S4) 72.35